REYKJAVIK, Iceland, June 08, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for AVT16, a proposed interchangeable biosimilar to Entyvio® (vedolizumab) lyophilized vial for intravenous administration.
VESALIUS-CV Subgroup Results Show Repatha® Reduces Risk of First Major Cardiovascular Events by 29% in People Living with High-Risk DiabetesNew Real-World Data Highlight Treatment...
We are investigating whether Jefferies Financial Group Inc. & certain of its top executives made materially false &/or misleading statements to investors.
The article explains how property conditions, inspection services, and home size can influence home inspection costs for buyers.BOURBONNAIS, Ill., June 5, 2026 /PRNewswire/ --...
Recommendations based on evaluations from top safety and consumer organizationsFive models recognized as "Best" choices for teen drivers, including Crosstrek, Forester, Solterra, Legacy, and...
Immersive job gives one lucky fan the beer education of a lifetimePETALUMA, Calif., June 5, 2026 /PRNewswire/ -- The Lagunitas Brewing Company is inviting craft beer and...
Rate reductions and California Climate Credits help lower summer energy costs for customersSAN DIEGO, June 5, 2026 /PRNewswire/ -- San Diego Gas & Electric...
The line-up includes two new para-athletes – Indonesian para cyclist Muhammad Fadli Imamuddin and Malaysian para-athletics sprinter Muhammad Ammar Aiman Nor Azmi – alongside...
The article explains how to evaluate transparency, consistency, and preventative maintenance when selecting an auto repair company.SOUTHINGTON, Conn., June 5, 2026 /PRNewswire/ -- What...